Alebund Pharmaceuticals Raises $60 Million In Series B Financing Round To Accelerate Its Development Of Innovative Drugs And Total Solutions For The Treatment Of Renal Diseases
Alebund Pharmaceuticals Raises $60 Million In Series B Financing Round To Accelerate Its Development Of Innovative Drugs And Total Solutions For The Treatment Of Renal Diseases
05/10/21, 12:17 AM
Location
shanghaiMoney raised
$60 million
Round Type
series b
Alebund Pharmaceuticals ("Alebund" or the "Company"), a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, today announced that it has raised $60 million in its Series B financing round which was led by Quan Capital, and followed by a prominent sovereign wealth fund, 3E Bioventures Capital, and Sherpa Healthcare Partners. Existing Shareholders, Lilly Asia Ventures and Med-Fine Capital, also took part in this financing round. Proceeds raised from this round will be invested in the research and development of pre-clinical assets, clinical programs, the construction of the manufacturing site, and the expansion of Company's talent pool.
Company Info
Location
shanghai, shanghai, china
Additional Info
Alebund is a clinical stage biopharmaceutical company and is dedicated to the discovery and development of novel therapies and to providing better clinical solutions to patients with kidney diseases and related chronic conditions.
Alebund has built a diversified and balanced pipeline of drug candidates targeting a range of renal diseases, including chronic kidney disease (CKD)/dialysis complications, IgA nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease (ADPKD). Alehund's pipeline comprises both small-molecule and biologic assets.